Bristol-Myers Squibb Company (BMY) and AstraZeneca (AZN) announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA ® (dapagliflozin 10 mg), in patients with ...

AstraZeneca) and 10 mg of the SGLT2 inhibitor dapagliflozin (Forxiga/Farxiga, AstraZeneca) for the treatment of type 2 diabetes in adults, according to a news release from AstraZeneca. Qtern is ...

AstraZeneca Pharma India on Monday said it has received approval for extended indication from the Drugs Controller General of India for Dapagliflozin 10 mg tablets. The receipt of this permission ...

Perspective from Roger S. Blumenthal, MD In the overall DECLARE-TIMI 58 CV outcome trial, dapagliflozin 10 mg (Farxiga, AstraZeneca) reduced the composite endpoint of CV death and HF ...

New Delhi: AstraZeneca Pharma India on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for Dapagliflozin tablets for the treatment of patients with chronic ...

and AstraZeneca (NYSE: AZN) today announced results from two 24-week Phase 3 clinical studies examining the investigational compound dapagliflozin at 5 mg or 10 mg (clinical trial dose ...

To assess the efficacy and safety of early dapagliflozin (Farxiga, AstraZeneca ... were randomly assigned to dapagliflozin 10 mg once daily or structured usual care with protocolized diuretic ...

LONDON (Alliance News) - AstraZeneca (AZN ... The patients treated with dapagliflozin 10 mg as an add-on therapy to metformin plus sulfonylurea, met key secondary endpoint of less than 7 percent ...

Bristol-Myers Squibb and AstraZeneca announced positive results ... mg/dL for dapagliflozin 5 mg and -23.5 mg/dL /dl for dapagliflozin 10 mg, compared to -6.0 mg/dL for placebo.

1 Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca ... 10.5%) were randomised to receive either placebo or dapagliflozin ...